KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Net Margin (2018 - 2025)

Historic Net Margin for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 67975.42%.

  • Vir Biotechnology's Net Margin fell 589957100.0% to 67975.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 2963.54%, marking a year-over-year decrease of 22851400.0%. This contributed to the annual value of 703.4% for FY2024, which is 102900.0% up from last year.
  • According to the latest figures from Q3 2025, Vir Biotechnology's Net Margin is 67975.42%, which was down 589957100.0% from 9139.87% recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's Net Margin peaked at 106.57% during Q3 2021, and registered a low of 67975.42% during Q3 2025.
  • Over the past 5 years, Vir Biotechnology's median Net Margin value was 690.85% (recorded in 2023), while the average stood at 6127.76%.
  • Its Net Margin has fluctuated over the past 5 years, first soared by 85902100bps in 2022, then crashed by -589957100bps in 2025.
  • Vir Biotechnology's Net Margin (Quarter) stood at 64.63% in 2021, then crashed by -418bps to 205.63% in 2022, then plummeted by -236bps to 690.85% in 2023, then decreased by -22bps to 845.23% in 2024, then plummeted by -7942bps to 67975.42% in 2025.
  • Its Net Margin was 67975.42% in Q3 2025, compared to 9139.87% in Q2 2025 and 3989.61% in Q1 2025.